COMMUNIQUÉS West-GlobeNewswire

Prodeon Medical Highlights the Urocross Expander System Clinical Results at the American Urological Association (AUA) 2026 Annual Meeting
28/04/2026
Company’s prospective, multi-center 240-patient, pivotal randomized controlled trial (RCT) earns AUA “Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s)” designation at conference’s Plenary Session [...]
CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation
28/04/2026
Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human [...]
TOMI Environmental Solutions to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today, April 28, 2026, at 1 p.m. ET
28/04/2026
Livestream to Highlight TOMI’s Innovation Acceleration Business Model and Global Decontamination Growth Strategy FREDERICK, Md., April 28, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: [...]
Ritedose Reaches “1,000 Hours of Purpose”
28/04/2026
Employee-led initiative deepens Ritedose's commitment to Midlands nonprofits and the communities they serve COLUMBIA, S.C., April 28, 2026 (GLOBE NEWSWIRE) -- The Ritedose Corporation today announced a significant [...]
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
28/04/2026
Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on defined development milestones WATERTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Kestrel [...]
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
28/04/2026
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced [...]
Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
28/04/2026
Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA ™ ) technology [...]
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
28/04/2026
- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE [...]
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
28/04/2026
With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track [...]
Flyte Deploys Additional Vision Jets in the Northeast to Capture Surging Summer Demand
28/04/2026
Positioned to Meet Accelerating Travel Activity across New York City, The Hamptons, Nantucket and Martha’s Vineyard Scalable Short-Haul Luxury Aviation Platform Targeting Key Regional Travel Markets FORT MILL, S.C., [...]
Aveanna to Participate at the Barclays 30th Annual Leveraged Finance Conference
28/04/2026
ATLANTA, April 28, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Barclays 30 th Annual Leveraged Finance Conference in [...]
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
28/04/2026
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program Grand Cayman, Cayman Islands, April 28, 2026 ( [...]
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
28/04/2026
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, [...]
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
28/04/2026
Analyses of the higher dose of Wegovy ® (semaglutide 7.2 mg) and Wegovy ® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achieved Wegovy ® ( [...]
Biomolecular Holdings Announces Issuance of Foundational Patents for Revolutionary Tetrahedral Antibody Technology
28/04/2026
BURLINGAME, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Biomolecular Holdings LLC, a privately-held biotechnology company advancing next-generation antibody architectures, today announced that the United States Patent [...]
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
28/04/2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a [...]
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
28/04/2026
Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK [...]
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
28/04/2026
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 [...]

Pages